Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Transgene and ProBioGen Enter License Agreement for Individualized Cancer Vaccine Development
Nov 05, 2024•almost 2 years ago
Contract Type
partnership
Bas-RhinBiotechnologyHealth CareTherapeutics
Description
Transgene and ProBioGen have entered into a partnership to advance individualized cancer vaccine development. The collaboration aims to combine ProBioGen's specific production technology with Transgene's individualized cancer vaccine program and its myvac® platform.
Company Information
Company
Transgene
Location
Bas-Rhin, Grand Est, France
About
Transgene is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company’s clinical-stage programs consist of a portfolio of therapeutic vaccines and oncolytic viruses with the goal of indirectly or directly killing cancer cells.